Beijing FDA Gives Quick Nod For H7N9 Rapid Testing Agent
This article was originally published in PharmAsia News
Executive Summary
A H7N9 diagnostic testing agent developed by Beijing Kinghawk Pharmaceutical Co. Ltd and Beijing SinoMedgene Technology Co. Ltd. was approved by Beijing FDA under the green channel approval process. The test cuts the time for results to less than three hours, down from six hours.
You may also be interested in...
Beijing Quietly Charms Both MNCs And Specialty Biotechs In Effort To Establish China's Bio Valley
BEIJING - Aiming to carve a leading position in China's nascent biotech industry, Beijing has embarked on a project to grow the industry more than two-fold in three years. Dubbed the "G20 Project," the Beijing Leap-forward Development Program for Biopharmaceutical Industry seeks to transform the capital city into China's hub for biotech R&D and manufacturing
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.